

## Hydrix signs a \$1.48 million contract with Cyban for the expanded development of their non-invasive brain oxygen monitor

### Highlights

- The \$1.48m contract is for Hydrix to complete for Cyban a detailed design, construction & testing of engineering prototypes, and final verification
- Cyban's world-first non-invasive brain oxygen monitor continuously delivers reliable information to radically improve how brain injuries are detected, treated and managed
- Cyban is targeting a commercial market launch in CY2024
- Hydrix Ventures currently holds a 5.85% stake in Cyban

**Hydrix Limited (ASX: HYD)** ("Hydrix") is pleased to announce that it has been contracted by Cyban Pty Ltd ("Cyban") to continue the development of Cyban's next-generation brain oxygen monitor.

This \$1.48 million contract with Cyban follows the completion of the previous development work to refine and advance the proof-of-concept prototype to a commercial product, including the red/infrared sensor system, sensor interface, and patient monitoring unit.

This stage of the product development program is anticipated to be completed and revenue recognised during the next six months. Hydrix Services will leverage its powerful product innovation capability to deliver key product development engineering tasks, including:

- Detailed design, construction and testing of engineering prototypes inclusive of user interface design and development and preparation for verification testing; and
- Support a streamlined path for this product to achieve Class II medical device to FDA regulatory submission.

*"We are really pleased to be Cyban's development partner. Our teams are working very collaboratively to accelerate completion of the 1<sup>st</sup> generation of the product, which can potentially establish a new gold standard of care in brain trauma injury management" said Michael Trieu, General Manager of Hydrix Services.*

**-ENDS-**

**Authorisation:** This announcement is authorised for release by the Board of Directors of Hydrix Limited.

**Contact Details:** For more information, please contact:

**Company Enquiries:**

Gavin Coote

Executive Chairman

[info@hydrix.com](mailto:info@hydrix.com)

+61 3 9550 8100

**Media Enquires:**

Rod North

Managing Director, Bourse Communications

[rod@boursecommunications.com.au](mailto:rod@boursecommunications.com.au)

+61 3 9510 8309

**About Hydrix Limited**

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix aims to enhance a billion lives' health, safety, and well-being. The company leverages its powerful product innovation capability across three business segments: **Services:** design, engineer, and deliver world-first products and innovation; **Ventures:** invest in high potential medtech clients, and **Medical:** distribute disruptive cardiovascular products.

**About Cyban Pty Ltd**

Cyban is an Australian technology company focused on developing a novel, non-invasive continuous brain oxygen monitor. Initial commercialisation focus is on measuring and reporting cerebral blood perfusion, brain oxygen levels and intracranial pressure in intensive care units and operating theatres. This information can enable early detection and faster treatment of brain hypoxia (lack of oxygen to the brain).